Last month, American pharmaceutical company Eli Lilly ended its fourth study investigating the effectiveness of solanezumab, a potential drug therapy for people with mild cognitive impairment caused by Alzheimer’s disease. Researchers designed the eight-year trial, known as DIAN-TU, to test the therapy’s safety, tolerability, biomarker, and cognitive efficacy on participants with a genetic mutation that causes …
5xFAD Mice Cleared of Tau and Amyloid Proteins Through Light and Sound
The 5xFAD mouse is a popular rodent model in the preclinical Alzheimer’s disease research community. Recently, research performed on 5xFAD mice benefited Shanghai-based company Green Valley’s drug candidate Oligomannate, which was approved for clinical use in mild to moderate Alzheimer’s disease in China. In addition, 5xFAD mice were an integral part of another potentially important study in Alzheimer’s …
5xFAD Mice Offer Hope for Alzheimer’s Disease Research
Recently, the Shanghai-based company Green Valley announced approval of their drug candidate Oligomannate for clinical use in mild to moderate Alzheimer’s disease (AD) in China. This news made a big splash because nearly two decades have passed since the last approval of an Alzheimer’s drug. The successful approval of this drug was partially based on …
High Translational Value Biomarkers in Neurodegenerative Disease
Biomarkers are an emerging area of focus in neurodegenerative diseases. This new scrutiny has arisen because biomarkers may provide an important link between preclinical disease models and the evaluation of disease progression in patients. One of these biomarkers, neurofilament light chain (NF-L), a neuronal cytoplasmic protein, is increased in a variety of neuronal diseases due …
QPS Neuropharmacology Announces Cooperation with the University of Bari Aldo Moro for Autism Spectrum Disorder R&D Project
QPS Neuropharmacology and the research group of Marcello Leopoldo from the University of Bari Aldo Moro, Italy, are collaborating on a funded research project related to autism spectrum disorder (ASD). Funding by the Austrian Research Promotion Agency (FFG) to perform the whole study within the frame of the industry-related PhD program (“Industrienahe Dissertation”) has been …
How and Why In Vitro Testing Is a Benefit to Neuropharmacology
Preclinical trials and studies of all kinds involve a number of different types of testing, including in vivo, in situ, in silico, and in vitro testing. Briefly, in vivo testing is performed in or on a whole living organism (usually an animal), in situ testing occurs where the organism is found in nature, while in …
Exploring CAA as an Independent Risk Factor for Cognitive Dysfunction or Alzheimer’s Disease
Are you looking to explore Cerebral Amyloid Angiopathy (CAA) as an independent risk factor for cognitive dysfunction or Alzheimer’s disease? QPS Austria, one of the top preclinical and clinical CROs in Europe, is ready to partner with you to provide visualization and quantification of CAA in murine tissues. In the last five years, there has …
